Compare Biogen Inc (BIIB) vs Nu Holdings Ltd (NU) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

NU stock trades at $13.615, down 1.77% on the day, amid bearish technical signals but strong fundamentals. Revenue grew from $3.0B in 2022 to $10.63B in 2025, with net income turning positive to $2.87B. The company recently announced a Brazilian banking license acquisition (PYMNTS, 2026-07-22), supporting expansion. Analysts maintain a buy consensus with a $14.98 target, though recent earnings misses and competitive pressures pose headwinds.

Outlook: NU's robust growth trajectory and high ROE (30.04% as of 2025) offer upside, but technical weakness and Latin American market risks require caution. The Q2 2026 earnings report on August 13 (Defense World, 2026-08-12) is a key catalyst, with expectations of $0.1984 EPS. Investors should weigh strong profitability against bearish momentum and rising competition.